Ocugen Launches Pivotal Gene Therapy Trial for Vision-Threatening Geographic Atrophy

Key Points

• Ocugen has dosed the first patient in ArMaDa3, its global Phase 3 registrational trial of OCU410 for geographic atrophy caused by dry age-related macular degeneration.
• The 237-patient study will compare a one-time subretinal injection of OCU410 with an untreated control group.
• The primary measure is the rate of geographic atrophy lesion growth through 12 months, assessed by fundus autofluorescence imaging.
• The FDA granted OCU410 Regenerative Medicine Advanced Therapy designation in July 2026, and Ocugen expects a single successful Phase 3 trial could support a planned Biologics License Application filing in 2028.

Ocugen (Nasdaq: OCGN) has started patient dosing in its pivotal Phase 3 trial of OCU410, moving the company’s gene-therapy candidate for geographic atrophy secondary to dry age-related macular degeneration into its registration-stage development program.

The global study, called ArMaDa3, is evaluating OCU410, also known as AAV5-hRORA, as a potential one-time treatment for geographic atrophy, an advanced form of dry AMD that causes irreversible loss of retinal tissue and can progressively impair central vision.

Global Study Tests One-Time Treatment

ArMaDa3 is designed to enroll 237 patients with geographic atrophy secondary to dry AMD across clinical sites in the United States, Canada, Europe, and Latin America.

Participants will be randomized on a 2-to-1 basis. Patients in the treatment arm will receive a single 200-microliter subretinal injection of OCU410, while patients in the control arm will receive no treatment. OCU410 is designed as a modifier gene therapy intended to address multiple biological pathways associated with geographic atrophy.

Lesion Growth Is the Primary Endpoint

The main goal of the study is to evaluate whether OCU410 slows the rate at which geographic atrophy lesions expand. Investigators will measure lesion area using fundus autofluorescence imaging at baseline and at months four, eight, and 12.

Secondary measures include assessments of functional vision and preservation of the ellipsoid zone, a retinal biomarker associated with photoreceptor integrity and visual function.

FDA Alignment Supports Single-Trial Path

Ocugen said the Phase 3 launch follows a Type B end-of-Phase 2 meeting with the FDA’s Center for Biologics Evaluation and Research in July 2026. According to the company, the meeting produced alignment on key aspects of the Phase 3 program, including the dose, primary and secondary endpoints, adaptive study design, and use of one pivotal study as the potential basis for a Biologics License Application.

The FDA also granted OCU410 RMAT designation on July 29, 2026. The designation provides increased FDA interaction and may allow Ocugen to seek accelerated approval and priority review, but it does not constitute FDA approval of OCU410.

Phase 2 Results Set the Stage

The Phase 3 program follows positive 12-month data from Ocugen’s Phase 2 ArMaDa trial. In that study, 51 patients age 50 and older were randomized among medium-dose OCU410, high-dose OCU410, and untreated control arms.

Ocugen reported that the medium dose achieved a statistically significant 31% reduction in geographic atrophy lesion growth at 12 months versus the untreated control group. The Phase 2 study also evaluated ellipsoid-zone preservation as an exploratory measure.

While the prior study informed the Phase 3 design, Phase 2 findings do not guarantee that OCU410 will produce similar efficacy or safety results in the larger registrational trial.

Investor Focus: Execution and 2028 Filing Goal

First-patient dosing marks a meaningful operational milestone for Ocugen, but it does not provide new clinical efficacy data. Investors will be watching enrollment pace, site activation, safety observations, interim assessments, and the eventual 12-month data set required to evaluate the program’s primary endpoint.

Ocugen expects to file a Biologics License Application for OCU410 in 2028 if the ArMaDa3 trial is successful. The timeline remains subject to clinical-trial execution, efficacy and safety outcomes, FDA review, manufacturing readiness, and regulatory requirements. OCU410 is investigational and has not been approved for use by the FDA or other regulators.